Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset...